Nanosafety vs. nanotoxicology: adequate animal models for testing in vivo toxicity of nanoparticles

Криштоп, В. В.; Prilepskii, Artur Y.; Nikonorova, V.G.; Mironov, Vladimir

doi:10.1016/j.tox.2021.152952

Cited by 25 publications

(16 citation statements)

References 175 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are several reviews on the neurotoxicology that follows from the accumulation of nanomaterials in the brain [936][937][938][939][940]. The greatest toxicity is observed with the chronic administration of either metallic NPs or CNTs/fullerenes.…”

Section: Nanoparticle Neurotoxicologymentioning

confidence: 99%

A Historical Review of Brain Drug Delivery

Pardridge

2022

Pharmaceutics

106

View full text Add to dashboard Cite

The history of brain drug delivery is reviewed beginning with the first demonstration, in 1914, that a drug for syphilis, salvarsan, did not enter the brain, due to the presence of a blood–brain barrier (BBB). Owing to restricted transport across the BBB, FDA-approved drugs for the CNS have been generally limited to lipid-soluble small molecules. Drugs that do not cross the BBB can be re-engineered for transport on endogenous BBB carrier-mediated transport and receptor-mediated transport systems, which were identified during the 1970s–1980s. By the 1990s, a multitude of brain drug delivery technologies emerged, including trans-cranial delivery, CSF delivery, BBB disruption, lipid carriers, prodrugs, stem cells, exosomes, nanoparticles, gene therapy, and biologics. The advantages and limitations of each of these brain drug delivery technologies are critically reviewed.

show abstract

Section: Nanoparticle Neurotoxicologymentioning

confidence: 99%

A Historical Review of Brain Drug Delivery

Pardridge

2022

Pharmaceutics

106

View full text Add to dashboard Cite

show abstract

“…Afterwards, the obtained results, usually based on acute exposure, may indicate no potential risk of the nanomedicine in clinics. However, chronic exposure to less toxic concentrations for a prolonged time may require an adjustment of the therapeutic scheme and the reassessment of the safety and efficacy of the nanomedicine …”

Section: Methods For Nanotoxicity Assessmentmentioning

confidence: 99%

“…275 Despite the crucial output addressed by in vitro platforms, the assessment of pharmacokinetic/toxicokinetic parameters remains a limitation. Therefore, the use of in vivo models is the gold standard laboratory testing protocol to determine toxicities 279,280 in compliance with the strategy of replacing, reducing, and refining the use of laboratory animal experiments. 275 In Vivo.…”

Section: Methods For Nanotoxicity Assessmentmentioning

confidence: 99%

Where Is Nano Today and Where Is It Headed? A Review of Nanomedicine and the Dilemma of Nanotoxicology

et al. 2022

View full text Add to dashboard Cite

Worldwide nanotechnology development and application have fueled many scientific advances, but technophilic expectations and technophobic demands must be counterbalanced in parallel. Some of the burning issues today are the following: (1) Where is nano today? (2) How good are the communication and investment networks between academia/research and governments? (3) Is there any spotlight application for nanotechnology? Nanomedicine is a particular arm of nanotechnology within the healthcare landscape, focused on diagnosis, treatment, and monitoring of emerging (such as coronavirus disease 2019, COVID-19) and contemporary (including diabetes, cardiovascular diseases, neurodegenerative disorders, and cancer) diseases. However, it may only represent the bright side of the coin. In fact, in the recent past, the concept of nanotoxicology has emerged to address the dark shadows of nanomedicine. The nanomedicine field requires more nanotoxicological studies to identify undesirable effects and guarantee safety. Here, we provide an overall perspective on nanomedicine and nanotoxicology as central pieces of the giant puzzle of nanotechnology. First, the impact of nanotechnology on education and research is highlighted, followed by market trends and scientific output tendencies. In the next section, the nanomedicine and nanotoxicology dilemma is addressed through the interplay of in silico, in vitro, and in vivo models with the support of omics and microfluidic approaches. Lastly, a reflection on the regulatory issues and clinical trials is provided. Finally, some conclusions and future perspectives are proposed for a clearer and safer translation of nanomedicines from the bench to the bedside.

show abstract

“…Year-long analyses are rarely examined in research primarily due to time constraints despite being informative and essential [ 47 ]. Nonetheless, these are all considerable parameters when examining in vivo nanotoxicity, with several current methods needing improved testing parameters and animal models for more accurate toxicity assessments, especially when examining the complexity of human health [ 48 ]. The most commonly used in vivo analysis methods are listed in Table 2 [ 23 ].…”

Section: Current Methods and Concerns For In Vivo Nanotoxicity Determ...mentioning

confidence: 99%

Analysis of Nanomaterials on Biological and Environmental Systems and New Analytical Methods for Improved Detection

Reagen

Zhao

2022

IJMS

View full text Add to dashboard Cite

The advancing field of nanoscience has produced lower mass, smaller size, and expanded chemical composition nanoparticles over recent years. These new nanoparticles have challenged traditional analytical methods of qualification and quantification. Such advancements in nanoparticles and nanomaterials have captured the attention of toxicologists with concerns regarding the environment and human health impacts. Given that nanoparticles are only limited by size (1–100 nm), their chemical and physical characteristics can drastically change and thus alter their overall nanotoxicity in unpredictable ways. A significant limitation to the development of nanomaterials is that traditional regulatory and scientific methods used to assess the biological and environmental toxicity of chemicals do not generally apply to the assessment of nanomaterials. Significant research effort has been initiated, but much more is still needed to develop new and improved analytical measurement methods for detecting and quantitating nanomaterials in biological and environmental systems.

show abstract

Nanosafety vs. nanotoxicology: adequate animal models for testing in vivo toxicity of nanoparticles

Cited by 25 publications

References 175 publications

A Historical Review of Brain Drug Delivery

A Historical Review of Brain Drug Delivery

Where Is Nano Today and Where Is It Headed? A Review of Nanomedicine and the Dilemma of Nanotoxicology

Analysis of Nanomaterials on Biological and Environmental Systems and New Analytical Methods for Improved Detection

Contact Info

Product

Resources

About